Patent ID: 6596477
Filing Date: 2003-07-22
Classification: A61K,Y02A

Abstract:
An in vitro method of reducing human immunodeficiency virus (HIV) replication in mononuclear cells comprising:introducing a composition to the mononuclear cells comprising a lipopolysaccharide (LPS) variant in an amount effective to reduce HIV replication therein, wherein the LPS variant is an isolated LPS component obtained from a double mutant E. coli which is designated E coli htrB1::Tn10 msbB.::&OHgr;cam strain having ATCC Accession No. PTA-2794, and wherein the LPS variant has the following properties: (a) exhibits reduced pyrogenicity relative to a wild-type E. coli lipopolysaccharide; (b) stimulates secretion of &bgr;-chemokines from mononuclear cells; (c) exhibits decreased induction of TNF-&agr; proinflammatory secretion relative to a wild-type E. Coli lipopolysaccharide; and (d) reduces HIV replication in the mononuclear cells.